Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Change in Accured Expenses: 2009-2024

Historic Change in Accured Expenses for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to $13.9 million.

  • Ligand Pharmaceuticals' Change in Accured Expenses fell 50.92% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year increase of 82.79%. This contributed to the annual value of $13.9 million for FY2024, which is 395.56% up from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Change in Accured Expenses of $13.9 million as of FY2024, which was up 395.56% from -$4.7 million recorded in FY2023.
  • Ligand Pharmaceuticals' 5-year Change in Accured Expenses high stood at $13.9 million for FY2024, and its period low was -$4.7 million during FY2023.
  • Its 3-year average for Change in Accured Expenses is $2.0 million, with a median of -$3.3 million in 2022.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Change in Accured Expenses crashed by 218.86% in 2022, and later surged by 395.56% in 2024.
  • Yearly analysis of 5 years shows Ligand Pharmaceuticals' Change in Accured Expenses stood at -$1.2 million in 2020, then soared by 325.70% to $2.8 million in 2021, then tumbled by 218.86% to -$3.3 million in 2022, then crashed by 40.84% to -$4.7 million in 2023, then skyrocketed by 395.56% to $13.9 million in 2024.